



ASX and MEDIA Announcement

NASDAQ PROGRESSION ANNOUNCEMENT – MEDLAB CLEARS SEC COMMENTS

Sydney, December 8, 2022 - Medlab Clinical Ltd (ASX:MDC) (Medlab, the Company), is very pleased to announce that the Company's filing has cleared Securities Exchange Commission (SEC) comments.

Medlab is finalising its NASDAQ application (reserved symbol: MDLB) and continues to work with our US bank, AGP.

Dr. Sean Hall, CEO of Medlab states: "We can't talk about the deal at this point as the bank is not yet marketing the stock. That time is coming. For now, we wanted to inform our current shareholders of the Nasdaq progression and remind everyone that the goal is for ordinary stocks trading on both the ASX and Nasdaq, i.e., dual listed."

- ENDS -

Authorisation & Additional information

This announcement was authorised by the Board of Directors of Medlab Clinical Limited.

About Medlab Clinical:

Medlab Clinical LTD (ASX:MDC) is pioneering the use of NanoCelle® a proprietary, patented delivery technology using water soluble nanoparticles®, allowing for enhanced medical properties, including increased efficacy, safety, patient compliance and stability.

Medlab's investigative drug pipeline comprises several small and large molecules from repurposing generic medicines to enhancing the delivery of immunotherapies.

Patented lead drug candidate NanaBis™ is being developed for cancer bone pain as a viable alternative to opioid use. Data to date, strongly suggests NanaBis™ may be equally effective in non-cancer neuropathic pain. Medlab operates in Australia (Head Office), USA, and the UK.

For more information, please visit www.medlab.co

Medlab – *better medicines, better patient care*

For further information contact:

Dr. Sean Hall, CEO, Medlab Clinical Ltd

T: +61 411 603 378

E: sean_hall@medlab.co